Jul 31, 2022
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC
Jul 28, 2022
Immutep Quarterly Activities Report
Jul 05, 2022
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Jun 26, 2022
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
Jun 03, 2022
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Jun 01, 2022
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
May 27, 2022
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
May 04, 2022
Immutep Presents New and Significant Data from the AIPAC Study
Apr 28, 2022
Apr 27, 2022
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
Mar 29, 2022
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
Mar 23, 2022
Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022
